SURPASS-3 Trial: Tirzepatide vs Insulin Degludec — Superior Glucose Control With Weight Loss Instead of Gain
Medically reviewed by Dr. James Whitfield, DO, FACOI
The SURPASS-3 trial, published in The Lancet in 2021 by Ludvik et al., compared tirzepatide against insulin degludec in 1,444 patients with type 2 diabetes. The results were striking: tirzepatide 15mg reduced HbA1c by 2.37% with 12.9kg weight loss, while insulin degludec reduced HbA1c by only 1.34% with 2.3kg weight gain — a 15.2kg difference in body weight.
SURPASS-3: Rewriting the Insulin Paradigm
For decades, insulin has been the cornerstone of type 2 diabetes treatment when oral medications fail. The SURPASS-3 trial, published in The Lancet in October 2021 by Ludvik et al., challenged this paradigm by demonstrating that tirzepatide not only matched but dramatically exceeded insulin degludec in glycemic control — while producing massive weight loss instead of the weight gain that plagues insulin therapy [1].
Study Design
SURPASS-3 was a 52-week, open-label, randomized Phase 3 trial conducted at 122 sites across 13 countries. It enrolled 1,444 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor.
Randomization (1:1:1:1):
Insulin degludec (Tresiba) was chosen as the comparator because it represents a modern, long-acting basal insulin with a favorable safety profile and low hypoglycemia risk — making it a strong comparator [1].
---
> Interested in starting a supervised protocol? Telegenix offers telehealth peptide and TRT programs with ongoing lab monitoring and provider support. Book your free consultation today.
---
Glycemic Control: Tirzepatide Dominates
Mean HbA1c Change from Baseline (~8.2%):
Treatment Difference vs. Insulin (15 mg): -1.04% (P<0.001)
HbA1c Target Achievement:
The fact that tirzepatide achieved nearly a full percentage point more HbA1c reduction than optimally titrated insulin is remarkable. Insulin has long been considered the most potent glucose-lowering therapy, yet tirzepatide surpassed it decisively [1].
The Weight Story: Loss vs. Gain
The weight data represents the most dramatic contrast:
Mean Body Weight Change:
Total Weight Difference (15 mg vs. insulin): 15.2 kg (33.5 lbs)
This 15.2 kg difference is clinically enormous. A patient choosing tirzepatide over insulin would weigh approximately 33 pounds less after one year — while achieving better glucose control [1].
Why Insulin Causes Weight Gain
Understanding why insulin promotes weight gain helps explain tirzepatide's advantage:
Tirzepatide avoids all of these mechanisms while providing superior glucose lowering through appetite reduction, improved insulin sensitivity, and glucose-dependent insulin secretion [2].
Safety Comparison
Hypoglycemia (<54 mg/dL):
The dramatically lower hypoglycemia rate with tirzepatide is a major safety advantage. Hypoglycemia is the most feared complication of insulin therapy, limiting dose titration and causing significant anxiety.
Gastrointestinal Events:
Discontinuation due to AEs:
Liver Fat Reduction
A notable secondary finding was tirzepatide's effect on liver fat:
Clinical Implications
SURPASS-3 has several practice-changing implications:
> Related Comparison: MOTS-C vs Metformin: Metabolic Comparison
> Related Comparison: Ozempic vs Mounjaro: Complete Comparison
References
---
> From research to results — get expert guidance. Telegenix specializes in physician-supervised peptide therapy and testosterone optimization. Schedule your free consultation and start your personalized protocol.
---
Related Reading
Explore more in-depth guides on related topics:
For a comprehensive overview, see our Complete Guide to Peptide Therapy. For a deeper dive into this area, see peptide monitoring blood panels.
---